StockIQpro
NASDAQ:GOSS

Gossamer Bio, Inc.

Track all markets on TradingView
Track all markets on TradingView

Gossamer Bio, Inc.'s revenue fell 57.7% in fiscal 2025 to $48.5M while operating margin fell to −352.2%. Free cash flow was −$171.3M, −353.5% of revenue, and the diluted share count rose 1.0%.Summary generated from Gossamer Bio, Inc.'s SEC filings. Latest annual report filed Mar 17, 2026.

Key statistics

Fiscal 2025 from SEC filings. Methodology
Revenue (FY25)$48.5M
Revenue growth−57.7%
Revenue, 5-yr CAGRn/a
Gross marginn/a
Operating margin−352.2%
Net margin−351.5%
ROICn/a
Return on equityn/a
Debt / equityn/a
Free cash flow−$171.3M
FCF margin−353.5%
Share count change+1.0%

Financials

Fiscal years, $M
Item20212022202320242025
Revenuen/a0011548
Operating income−216−219−184−60−171
Net income−234−229−180−57−170
Free cash flow−190−187−159−3−171

Recent filings

From SEC EDGAR

Peers

Pharmaceutical preparations